Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential

Abstract: The purpose of this analysis was to assess the potential of BNCT, with L-boronophenylalanine (L-BPA), as first line radiotherapy for glioblastoma multiforme (GBM). The survival of patients with newly diagnosed GBM from a phase II BNCT study was compared with those from the two arms of a phase Ill study with conventional radiotherapy (RT) vs. RT plus concomitant and adjuvant medication with temozolomide (TMZ). A small subgroup, for which the methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) DNA-repair gene was known, was also considered. The results indicated that the use of BNCT with BPA should be explored in a stratified randomized phase II trial in which patients with the unmethylated MGMT DNA-repair gene are offered BNCT vs. RT plus TMZ. (C) 2011 Elsevier Ltd. All rights reserved.

Gorlia, T (författare)
Pellettieri, LGothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology (författare)
Giusti, V (författare)
H-Stenstam, B (författare)
Skold, K (författare)
Göteborgs universitetInstitutionen för neurovetenskap och fysiologi (creator_code:org_t)

Av författaren/redakt...: Hopewell, JW; Gorlia, T; Pellettieri, L; Giusti, V; H-Stenstam, B; Skold, K

Om ämnet

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.